Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC)

References

• Are C, Chowdhury S, Ahmad H, et al. Predictive global trends in the incidence and mortality of pancreatic cancer based on geographic location, socio-economic status, and demographic shift. J Surg Oncol. 2016;114(6):736–742.
   PubMed Web of Science ®Google Scholar
• Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol [Internet]. 2016 [cited 2018 Dec 19];22(44):9694–9705. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124974/
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
   PubMed Web of Science ®Google Scholar
• Kamarajah SK, Burns WR, Frankel TL, et al. Validation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with pancreatic adenocarcinoma: a Surveillance, Epidemiology and End Results (SEER) analysis. Ann Surg Oncol. 2017;24(7):2023–2030.
   PubMed Web of Science ®Google Scholar
• Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw JNCCN. 2017;15(8):1028–1061.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703.
   PubMed Web of Science ®Google Scholar
• Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol Off J Am Soc Clin Oncol. 1997;15(6):2403–2413.
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A, Li C-P, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet Lond Engl. 2016;387(10018):545–557.
   PubMed Web of Science ®Google Scholar
• Cartwright TH, Parisi M, Espirito JL, et al. Clinical outcomes with first-line chemotherapy in a large retrospective study of patients with metastatic pancreatic cancer treated in a US community oncology setting. Drugs Real World Outcomes. 2018;5(3):149–159.
   PubMedGoogle Scholar
• Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(15):1960–1966.
   PubMed Web of Science ®Google Scholar
• Waddell N, Pajic M, Patch A-M, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495–501.
   PubMed Web of Science ®Google Scholar
• Chandana S, Babiker HM, Mahadevan D. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC). Expert Opin Investig Drugs. 2019;28(2):161–177.
   PubMed Web of Science ®Google Scholar
• Rowinsky EK. Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol. 2004;16(6):564–575.
   PubMed Web of Science ®Google Scholar
• Paquette M, El-Houjeiri L, Pause A. mTOR Pathways in Cancer and Autophagy. Cancers (Basel) [Internet]. 2018 [cited 2019 Jan 24];10(1):18. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789368/
   PubMed Web of Science ®Google Scholar
• Zhao T, Ren H, Li J, et al. LASP1 is a HIF1α target gene critical for metastasis of pancreatic cancer. Cancer Res. 2015;75(1):111–119.
   PubMed Web of Science ®Google Scholar
• Conciatori F, Ciuffreda L, Bazzichetto C, et al. mTOR Cross-Talk in Cancer and Potential for Combination Therapy. Cancers (Basel) [Internet]. 2018 [cited 2019 Jan 24];10(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789373/
   PubMed Web of Science ®Google Scholar
• Choi J, Chen J, Schreiber SL, et al. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science. 1996;273(5272):239–242.
   PubMed Web of Science ®Google Scholar
• Tuncyurek P, Mayer JM, Klug F, et al. Everolimus and mycophenolate mofetil sensitize human pancreatic cancer cells to gemcitabine in vitro: a novel adjunct to standard chemotherapy? Eur Surg Res [Internet]. 2007 [cited 2018 Dec 20];39(6):380–387. Available from: https://www.karger.com/Article/FullText/107356
   PubMed Web of Science ®Google Scholar
• Peng T, Dou QP. Everolimus inhibits growth of gemcitabine-resistant pancreatic cancer cells via induction of caspase-dependent apoptosis and G2/M arrest. J Cell Biochem. 2017;118(9):2722–2730.
   PubMed Web of Science ®Google Scholar
• Pawaskar DK, Straubinger RM, Fetterly GJ, et al. Interactions of everolimus and sorafenib in pancreatic cancer cells. AAPS J [Internet]. 2012 [cited 2018 Dec 20];15(1):78–84. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3535103/
   PubMed Web of Science ®Google Scholar
• O’Reilly KE, Rojo F, She Q-B, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66(3):1500–1508.
   PubMed Web of Science ®Google Scholar
• Wei F, Zhang Y, Geng L, et al. mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer. Int J Mol Sci. 2015;16(2):3267–3282.
   PubMed Web of Science ®Google Scholar
• Pawaskar DK, Straubinger RM, Fetterly GJ, et al. Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. Cancer Chemother Pharmacol [Internet]. 2013 [cited 2018 Dec 20];71(5):1231–1240. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3752659/
   PubMed Web of Science ®Google Scholar
• nexavar-pm-en-pt3.pdf [Internet]. [cited 2018 Dec 20]. Available from: https://www.bayer.ca/omr/online/nexavar-pm-en-pt3.pdf
   Google Scholar
• Lasithiotakis KG, Sinnberg TW, Schittek B, et al. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol. 2008;128(8):2013–2023.
   PubMed Web of Science ®Google Scholar
• Molhoek KR, Brautigan DL, Slingluff CL. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J Transl Med [Internet]. 2005 [cited 2018 Dec 20];3(1):39. Available from: https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-3-39
   PubMedGoogle Scholar
• Newell P, Toffanin S, Villanueva A, et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol. 2009;51(4):725–733.
   PubMed Web of Science ®Google Scholar
• Wei F, Liu Y, Guo Y, et al. miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer. Mol Cancer. 2013;12:81.
   PubMed Web of Science ®Google Scholar
• Witkiewicz AK, Balaji U, Eslinger C, et al. Integrated patient-derived models delineate individualized therapeutic vulnerabilities of pancreatic cancer. Cell Rep. 2016;16(7):2017–2031.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Rojo F, Calvo E, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(10):1603–1610.
   PubMed Web of Science ®Google Scholar
• Wolpin BM, Hezel AF, Abrams T, et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(2):193–198.
   PubMed Web of Science ®Google Scholar
• Kim ST, Lee J, Park SH, et al. Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy. BMC Cancer. 2017;17(1):211.
   PubMedGoogle Scholar
• Javle MM, Shroff RT, Xiong H, et al. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer. 2010;10:368.
   PubMed Web of Science ®Google Scholar
• Kordes S, Richel DJ, Klümpen H-J, et al. A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer. Invest New Drugs [Internet]. 2013 [cited 2018 Dec 20];31(1):85–91. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553409/
   PubMed Web of Science ®Google Scholar
• Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000;60(11):2926–2935.
   PubMed Web of Science ®Google Scholar
• Kordes S, Klümpen HJ, Weterman MJ, et al. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol [Internet]. 2015 [cited 2018 Dec 20];75(6):1135–1141. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4441736/
   PubMed Web of Science ®Google Scholar
• Costello BA, Borad MJ, Qi Y, et al. Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors. Invest New Drugs. 2014;32(4):710–716.
   PubMed Web of Science ®Google Scholar
• Joka M, Boeck S, Zech CJ, et al. Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding study. Anticancer Drugs. 2014;25(9):1095–1101.
   PubMed Web of Science ®Google Scholar
• Nogova L, Mattonet C, Scheffler M, et al. The combination of sorafenib and everolimus in patients with solid tumors: results of a phase I study. J Clin Oncol [Internet]. 2016 [cited 2018 Dec 20]. Available from: http://ascopubs.org/doi/abs/10.1200/jco.2011.29.15_suppl.e13613
   PubMedGoogle Scholar
• Tolcher AW, Bendell JC, Papadopoulos KP, et al. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. Ann Oncol Off J Eur Soc Med Oncol. 2015;26(1):58–64.
   PubMed Web of Science ®Google Scholar
• Weinberg BA, Wang H, Witkiewicz AK, et al. A phase I/II study of ribociclib plus everolimus in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) refractory to chemotherapy. J Clin Oncol [Internet]. 2018 [cited 2018 Dec 20]. Available from:: http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.TPS4150
   PubMedGoogle Scholar
• Franco J, Witkiewicz AK, Knudsen ES. CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. Oncotarget. 2014;5(15):6512–6525.
   PubMed Web of Science ®Google Scholar
• Franco J, Balaji U, Freinkman E, et al. Metabolic reprogramming of pancreatic cancer mediated by CDK4/6 inhibition elicits unique vulnerabilities. Cell Rep. 2016;14(5):979–990.
   PubMed Web of Science ®Google Scholar
• Feig C, Gopinathan A, Neesse A, et al. The pancreas cancer microenvironment. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18(16):4266–4276.
   PubMed Web of Science ®Google Scholar
• Ko AH, LoConte N, Tempero MA, et al. A Phase I Study of FOLFIRINOX Plus IPI-926, a hedgehog pathway inhibitor, for advanced pancreatic adenocarcinoma. Pancreas. 2016;45(3):370–375.
   PubMed Web of Science ®Google Scholar
• Catenacci DVT, Junttila MR, Karrison T, et al. Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(36):4284–4292.
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Zheng L, Bullock AJ, et al. HALO 202: randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(4):359–366.
   PubMed Web of Science ®Google Scholar
• Liss AS, Thayer SP. Therapeutic targeting of pancreatic stroma [Internet]. In: Grippo PJ, Munshi HG, editors. Pancreatic cancer and tumor microenvironment. Trivandrum (India): Transworld Research Network; 2012 [cited 2018 Dec 20]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK98931/
   Google Scholar
• Picozzi VJ, Rocha FG, Helton S, et al. Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC). J Clin Oncol [Internet]. 2017 [cited 2018 Dec 20]. Available from:: http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.4_suppl.365
   Google Scholar
• Klümpen H-J, Queiroz KCS, Spek CA, et al. mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(6):e150–e153.
   PubMed Web of Science ®Google Scholar
• Driscoll DR, Karim SA, Sano M, et al. mTORC2 Signaling drives the development and progression of pancreatic cancer. Cancer Res. 2016;76(23):6911–6923.
   PubMed Web of Science ®Google Scholar
• Fricke SL, Payne SN, Favreau PF, et al. MTORC1/2 inhibition as a therapeutic strategy for PIK3CA mutant cancers. Mol Cancer Ther [Internet]. 2018 [cited 2019 Jan 26]. molcanther.0510.2018. Available from: http://mct.aacrjournals.org/content/early/2018/11/13/1535-7163.MCT-18-0510
   PubMed Web of Science ®Google Scholar